Last updated: 20 days ago
AstraZeneca's Koselugo Gains EU Approval: A Breakthrough for NF1 Treatment
AstraZeneca's Form 6-K reveals Koselugo's EU approval for inoperable plexiform neurofibromas, based on promising KOMET trial results. A significant step for NF1 patients.